MedTrace Logo

Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia

NCT00231335 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-12-07

No results posted yet for this study

Summary

A primary hypothesis to be explored here is that, given its pharmacodynamic profile and hypothesized mechanisms associated with schizophrenia, escitalopram will, in comparison to placebo, be effective when added to risperidone or olanzapine treated group in reducing the severity of resistant symptoms, particularly existing subsyndromal anxiety and depression.

Conditions

Interventions

DRUG

escitalopram

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • Emory University

    lead OTHER

Principal Investigators

  • Dragan Bugarski-Kirola, MD · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-03-31
Completion
2007-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00231335 on ClinicalTrials.gov